{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:42:25Z","timestamp":1783579345533,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.bone.2011.11.028","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T00:46:31Z","timestamp":1323564391000},"page":"739-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin"],"prefix":"10.1016","volume":"50","author":[{"given":"Davide","family":"Gatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fracassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2011.11.028_bb0005","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jbmr.5650100402","article-title":"Assessment of involutional bone loss: methodological and conceptual problems","volume":"10","author":"Adami","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.11.028_bb0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bone.2011.11.028_bb0015","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.11.028_bb0020","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1210\/jc.2005-2370","article-title":"Sclerostin and Wnt signaling\u2014the pathway to bone strength","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.11.028_bb0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot\u2013containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bone.2011.11.028_bb0030","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2011.11.028_bb0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.bone.2011.11.028_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.bone.2011.11.028_bb0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.11.028_bb0050","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.11.028_bb0055","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.11.028_bb0060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jbmr.128","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.11.028_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-008-9179-5","article-title":"Intramuscular neridronate in postmenopausal women with low bone mineral density","volume":"83","author":"Adami","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2011.11.028_bb0070","article-title":"Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women","author":"Chung","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2011.11.028_bb0075","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.11.028_bb0080","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Sem\u00ebnov","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2011.11.028_bb0085","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.bone.2011.11.028_bb0090","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.11.028_bb0095","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2011.11.028_bb0100","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bone.2006.12.052","article-title":"Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading","volume":"40","author":"Follet","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2011.11.028_bb0105","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1359\/jbmr.080617","article-title":"Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo","volume":"23","author":"Plotkin","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2011.11.028_bb0110","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with Alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2011.11.028_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2011.11.028_bb0120","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signalling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.bone.2011.11.028_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211013676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328211013676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:37:11Z","timestamp":1762659431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328211013676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S8756328211013676"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2011.11.028","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2011.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}